Cost-effectiveness analysis of ainuovirine versus efavirenz in HIV population initiating first-line combination antiretroviral therapy

被引：0
|
作者：
Yang, Chenlu [1 ]
Mi, Yuanqi [2 ]
Zeng, Yuhong [3 ]
Cheng, Feng [4 ]
Zheng, Yufang [5 ]
Zhang, Chunyun [5 ]
Qin, Hong [5 ]
Zeng, Huatang [6 ]
Zhou, Mengge
机构：
[1] Chinese Acad Med Sci, Dept Epidemiol & Biostat, Inst Basic Med Sci, Beijing, Peoples R China
[2] Peking Union Med Coll, Sch Basic Med, Beijing, Peoples R China
[3] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[4] Third Mil Med Univ, Dept Epidemiol, Coll Prevent Med, Army Med Univ, Chongqing, Peoples R China
[5] Jiangsu Aidea Pharmaceut Co Ltd, Clin Res & Dev, Yangzhou, Jiangsu, Peoples R China
[6] Shenzhen Hlth Dev Res & Data Management Ctr, Shenzhen, Peoples R China
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2024年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P267
引用
收藏
页码：237 / 237
页数：1
相关论文
共 50 条
  • [41] A cost-effectiveness analysis of first-line controller therapies for persistent asthma
    Shih, Ya-Chen Tina
    Mauskopf, Josephine
    Borker, Rohit
    PHARMACOECONOMICS, 2007, 25 (07) : 577 - 590
  • [42] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
    Shepherd, Jonathan P.
    Carter-Brooks, Charelle M.
    Chermanksy, Christopher
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2018, 29 (08) : 1213 - 1219
  • [43] A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma
    Ya-Chen Tina Shih
    Josephine Mauskopf
    Rohit Borker
    PharmacoEconomics, 2007, 25 : 577 - 590
  • [44] Cost-effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan
    Maeda, Tomomi
    Moriwaki, Kensuke
    Morimoto, Kosuke
    Yoshioka, Takashi
    Goto, Rei
    Shimozuma, Kojiro
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 40 : 118 - 126
  • [45] Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Wen, Feng
    Huang, Peng
    Wu, Qiuji
    Yang, Yang
    Zhou, Kexun
    Zhang, Mengxi
    Li, Qiu
    CANCER MEDICINE, 2024, 13 (16):
  • [46] Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC
    Chen, Ping
    Li, Yinfeng
    Jing, Xiaomei
    Chen, Jing
    Chen, Shimei
    Yang, Qing
    LUNG CANCER, 2022, 174 : 157 - 164
  • [47] COST-EFFECTIVENESS OF VEDOLIZUMAB, INFLIXIMAB, AND ADALIMUMAB AS FIRST-LINE THERAPY FOR ULCERATIVE COLITIS
    Beilman, Candace L.
    Fedorak, Richard N.
    Halloran, Brendan P.
    GASTROENTEROLOGY, 2018, 154 (06) : S450 - S450
  • [48] THE COST-EFFECTIVENESS OF CATHETER ABLATION AS FIRST-LINE TREATMENT
    Aronsson, M.
    Walfridsson, H.
    Janzon, M.
    Walfridsson, U.
    Levin, L. A.
    VALUE IN HEALTH, 2013, 16 (07) : A529 - A529
  • [49] Cost-effectiveness of olanzapine as a first-line treatment: A comment
    Basu, Anirban
    VALUE IN HEALTH, 2006, 9 (05) : 357 - 357
  • [50] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN
    Baker, T. M.
    Paly, V. F.
    Thybo, S.
    Hultberg, M.
    Minacori, R.
    Kotapati, S.
    Sabater, J.
    VALUE IN HEALTH, 2016, 19 (07) : A730 - A731
12345